Significance of scheduling on the cytotoxicity of radiation and cisplatin combination treatment in nasopharyngeal carcinoma cells

被引:4
作者
Wang, XH
Chow, LSN
Nicholls, JM
Kwong, DLW
Sham, JST
Wong, YC
Tsao, SW
机构
[1] Univ Hong Kong, Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
关键词
cisplatin; nasopharyngeal carcinoma; radiation;
D O I
10.1097/00001813-200210000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of cisplatin as a potential radiosensitizer in nasopharyngeal carcinoma (NPC) has produced encouraging results in clinical trials. In order to provide information on improving the design of clinical treatments, we investigated the effect of cisplatin dose, and the time interval and sequence between administration of cisplatin and radiation on cell survival of two NPC cell lines, CNE1 and SUNE1. When cisplatin was applied first, an exposure time of 24 h resulted in up to 2.6-fold increase in cell death and 7-fold increase in radiation effect (cell survival after cisplatin/cell survival after cisplatin plus radiation) in the cisplatin-radiation combination treatment compared to the cells treated with cisplatin for 4 h. When radiation was applied first, a shorter interval time of 4 h followed by cisplatin treatment resulted in up to 3-fold increase in cell death and a 3-fold enhanced radiation effect over longer time intervals of 24 h. By changing the order of radiation and cisplatin treatment alone, a 24 old difference in radiation effect was observed. The differential cytotoxicity was partially explained by the alterations in cell cycle distribution. Our results indicate the importance of scheduling the radiation and cisplatin combination regimens on the survival of NPC cells. [(C) 2002 Lippincott Williams Wilkins.].
引用
收藏
页码:957 / 964
页数:8
相关论文
共 20 条
  • [1] [Anonymous], CHIN J CANC
  • [2] BELLAMY A S, 1984, Biochimica et Biophysica Acta, V738, P125, DOI 10.1016/0304-419X(84)90010-6
  • [3] BRISTOW RG, 1998, BASIC SCI ONCOLOGY, P295
  • [4] Chan ATC, 1998, CANCER-AM CANCER SOC, V82, P1003, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1003::AID-CNCR1>3.0.CO
  • [5] 2-F
  • [6] Geldof AA, 1999, ANTICANCER RES, V19, P505
  • [7] Gorodetsky R, 1998, INT J CANCER, V75, P635, DOI 10.1002/(SICI)1097-0215(19980209)75:4<635::AID-IJC23>3.0.CO
  • [8] 2-6
  • [9] GORODETSKY R, 1995, ISRAEL J MED SCI, V31, P95
  • [10] Isobe K, 1998, INT J ONCOL, V12, P1183